TMO - PerkinElmer Exiting The Pandemic In A Better Position For Long-Term Growth
- PerkinElmer posted better-than-expected results in Q4'21, with both COVID-19 and core businesses exceeding expectations.
- I believe management has been opportunistic with the COVID-19 windfall, reinvesting in M&A to better position the company for growth in areas like cytometry, cell therapy, and gene therapy.
- As is often the case in life sciences, PerkinElmer shares don't look conventionally cheap, but the valuation isn't as problematic relative to other life science stocks.
For further details see:
PerkinElmer Exiting The Pandemic In A Better Position For Long-Term Growth